SCHEMBL4285152

SCHEMBL4285152

COc1ccc(CN2CCC(N(C3CC3)S(=O)(=O)c3ccccc3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.56
ALDH1A1 P00352 2/20 0.54
CHRM2 P08172 2/20 0.54
CHRM3 P20309 2/20 0.54
LMNA P02545 1/20 0.54
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CACNA1B Q00975 1/20 0.53
ACHE P22303 2/20 0.49
BACE1 P56817 1/20 0.49
KDM4E B2RXH2 1/20 0.48
CXCR4 P61073 1/20 0.48
HTR2A P28223 1/20 0.48
MMP1 P03956 1/20 0.47
MMP9 P14780 1/20 0.47
MMP13 P45452 1/20 0.47
ADAM17 P78536 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997384 0.88 HTR2A (0.61) SIGMAR1CHRM2CHRM3CACNA1BACHE
SCHEMBL4277944 0.86 NPC1 (0.60) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL4285276 0.85 CHRM4 (0.56) CACNA1BCXCR4HTR2A
SCHEMBL7148857 0.85 MEN1 (0.56) SIGMAR1ALDH1A1CHRM2CHRM3LMNA
SCHEMBL4281857 0.85 CACNA1B (0.74) CACNA1B
SCHEMBL4282387 0.85 ALDH1A1 (0.51) SIGMAR1ALDH1A1CHRM2CHRM3CACNA1B
SCHEMBL4284277 0.84 HTR2A (0.48) ALDH1A1LMNACACNA1BACHECXCR4
SCHEMBL4286138 0.84 MEN1 (0.50) SIGMAR1LMNAKMT2AMEN1CACNA1B
SCHEMBL4283391 0.84 CACNA1B (0.56) ALDH1A1LMNAKMT2AMEN1CACNA1B
SCHEMBL4277843 0.82 ACHE (0.55) SIGMAR1ALDH1A1KMT2AMEN1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000174-B2 4-phenylsulfonamidopiperidines as calcium channel blockers PURDUE PHARMA L.P. (US) 2015-04-07 US disclosed
EP-1814851-B1 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO CELTIQUE SA (LU) 2013-06-05 EP disclosed
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers EURO-CELTIQUE S.A. (LU) 2009-04-23 US disclosed
CN-101044116-A 4-phenylsulfonamidopiperidines as calcium channel blockers EURO CELTIQUE SA (LU) 2007-09-26 CN disclosed
EP-1814851-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-08 EP disclosed
WO-2006040181-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers CACNA1A, CACNA1E, CACNA1B SIGMAR1 224/4885ALDH1A1 2001/4885CHRM2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.